



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-489

Bracco Diagnostics, Inc.
Attention: Melanie Benson
Director, US Regulatory Affairs
107 College Road East
Princeton, New Jersey 08540

Dear Ms. Benson:

Please refer to your new drug application (NDA) dated December 16, 2002, received December 17, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ProHance®, (Gadoteridol) Multipack™ Injection.

We acknowledge receipt of your submissions dated January 20 and 23, April 10, July 14, and September 22, 2003.

This new drug application provides for the use of ProHance® Multipack™ (Gadoteridol) Injection in an alternate packaging configuration, specifically, a container designated as a Pharmacy Bulk Package.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission “**FPL for approved NDA 21-489.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must submit patent information on form FDA 3542, *Patent Information Submitted Upon and After Approval of an NDA or Supplement*, within 30 days of the date of this letter as required by 21 CFR 314.53(c)(2)(ii) and 314.53(d)(2) at the address provided by 21 CFR 314.53(d)(4). The form may be obtained at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>. To expedite review of this patent declaration form, we request you submit an additional copy of the form to this application and to the Center for Drug Evaluation and Research "Orange Book" staff at

Food and Drug Administration
Office of Generic Drugs, HFD-610
Orange Book Staff
7500 Standish Place
Metro Park North II
Rockville, MD 20855-2773

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, call CAPT James Moore, Regulatory Project Manager, at (301) 827-7510.

Sincerely,

{See appended electronic signature page}

Sally Loewke, M.D.
Acting Division Director
Division of Medical Imaging and
Radiopharmaceutical Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Sally Loewke
10/9/03 04:45:07 PM